1. Scrip

Chronic Lymphocytic Leukemia Market To Grow Despite Biosimilar Wave

 
• By Lubna Ahmed

The chronic lymphocytic leukemia market is set to increase in size over the next decade despite an anticipated influx of biosimilars, new research by Datamonitor Healthcare finds. AbbVie/J&J's Imbruvica will remain the leading product, but the need for safe and effective therapies for relapsed and refractory CLL patients remains.

Destruction of leukaemia cell, conceptual image. 3D illustration which can be used to illustrate blood cancer treatment
• Source: Shutterstock

The chronic lymphocytic leukemia (CLL) market has been pegged to grow over the next nine years, with sales of major drugs in the US, Japan and the five major EU markets almost doubling from $3.5bn in 2016 to $6.1bn in 2025, Datamonitor Healthcare reports.

Between 2016 and 2025, the CLL market will see current therapies, such as AbbVie Inc./Johnson & Johnson's Imbruvica (ibrutinib) and AbbVie/Roche's Venclexta (venetoclax), increasing their sales and uptake, alongside the approval of several new pipeline therapies

CLL Drug Classes

PI3K inhibitors: Zydelig (idelalisib) and generic idelalisib, duvelisib

Anti-CD20s: Arzerra (ofatumumab), Rituxan (rituximab), biosimilar rituximab, Gazyva (obinutuximab) and ublituximab

BCL-2 inhibitors: Venclexta (venetoclax)

BTK inhibitors: Imbruvica

More from Anticancer

More from Therapy Areas